Top Page
Capstone Holding
(NASDAQ:CAPS)
Capstone Holding (CAPS) vs. SPDR S&P 500 ETF (SPY)
Capstone Holding Business Overview & Revenue Model
Capstone Holding Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 44.72M | 44.88M | 48.35M | 61.56M | 66.74M | 45.45M |
| Gross Profit | 9.78M | 9.57M | 9.61M | 16.53M | 16.32M | 10.94M |
| EBITDA | -2.86M | -121.00K | -1.75M | 4.23M | 5.02M | 2.64M |
| Net Income | -5.54M | -2.56M | -3.82M | 2.31M | 3.92M | 10.46M |
Balance Sheet | ||||||
| Total Assets | 58.48M | 47.22M | 52.70M | 65.21M | 60.85M | 54.87M |
| Cash, Cash Equivalents and Short-Term Investments | 730.00K | 11.00K | 52.00K | 23.00K | 50.00K | 0.00 |
| Total Debt | 23.25M | 16.61M | 20.33M | 28.80M | 28.34M | 20.81M |
| Total Liabilities | 31.33M | 50.28M | 50.26M | 57.04M | 31.78M | 25.77M |
| Stockholders Equity | 27.16M | -3.06M | 2.44M | 8.17M | 29.08M | 29.11M |
Cash Flow | ||||||
| Free Cash Flow | -1.17M | 3.70M | 1.24M | -3.06M | 2.55M | 639.00K |
| Operating Cash Flow | -1.15M | 3.82M | 1.45M | -2.89M | 3.72M | 642.00K |
| Investing Cash Flow | -2.46M | -120.00K | -208.00K | -173.00K | -931.00K | -3.00K |
| Financing Cash Flow | 4.32M | -3.74M | -1.21M | 3.04M | -2.74M | -697.00K |
Capstone Holding Technical Analysis
Capstone Holding Risk Analysis
Capstone Holding Peers Comparison
Capstone Holding Corporate Events
On January 7, 2026, Capstone Holding Corp. received notice from Nasdaq that its common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days, placing the company out of compliance with Nasdaq’s continued listing standards. The notification does not immediately affect trading of its shares, which continue to trade under the symbol “CAPS,” and Capstone has until July 6, 2026, to regain compliance, with the possibility of an additional 180-day extension if it meets other listing criteria; failure to do so could ultimately result in delisting, a development that would weigh on the stock’s liquidity and visibility for investors, while the company monitors its share price and considers options to restore compliance.
The most recent analyst rating on (CAPS) stock is a Hold with a $0.64 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
At its November 18, 2025 annual meeting, Capstone Holding Corp. shareholders unaffiliated with Nectarine Management LLC approved a letter agreement authorizing consent fees to Nectarine—owned by four Capstone directors and controlling the company’s Series B preferred stock—in return for its support on major corporate transactions such as mergers, significant asset deals, stock issuances, joint ventures and new debt. Following the December 1, 2025 acquisition of Fraser Canyon Holdings Inc., the board’s Nominating and Corporate Governance Committee on December 19, 2025 approved about $88,700 in fees and up to $50,000 in legal cost reimbursement to Nectarine tied to the cash portion of the deal, with additional contingent payments to Nectarine’s principals dependent on repayment of a CAD$3.6 million seller note and a CAD$3 million earn‑out, while subsidiary TotalStone, LLC simultaneously secured an extension of its $8.3 million revolving credit facility with Berkshire Bank to June 19, 2026, supporting ongoing liquidity and growth plans.
The most recent analyst rating on (CAPS) stock is a Hold with a $0.69 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
On December 15, 2025, Capstone Holding Corp. released an investor presentation detailing its 2026 strategy, emphasizing its growth through acquisitions and organic expansion. The company has successfully integrated recent acquisitions, achieving a $70 million revenue run rate, and is on track to meet its $100 million target by 2026. This strategy positions Capstone to capitalize on deferred construction demand, enhancing its market presence and shareholder value.
The most recent analyst rating on (CAPS) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
On December 1, 2025, Capstone Holding Corp. completed the acquisition of Canadian Stone Industries, a distributor with $15 million in annual revenue, which expands Capstone’s North American footprint and strengthens its brand portfolio. This acquisition is expected to immediately increase revenue and EBITDA, advancing Capstone towards its $100 million revenue target for early 2026, and reflects the company’s strategy of acquiring high-quality businesses to enhance its market position.
The most recent analyst rating on (CAPS) stock is a Hold with a $0.83 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
Capstone Holding Corp. has entered into a securities purchase agreement with an institutional investor, authorizing the issuance of senior secured convertible notes with an original principal amount of up to $10,909,885. On November 28, 2025, the company and the buyer agreed to reduce the conversion price of the July 2025 Convertible Note to $0.75 for the remaining principal amount of $500,744.01, and for $1,772,856.21 of the October 2025 Convertible Note, potentially impacting the company’s stock conversion strategy.
The most recent analyst rating on (CAPS) stock is a Hold with a $0.83 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
On November 18, 2025, Capstone Holding Corp. held its annual stockholders meeting where several key proposals were voted upon. The meeting, which had a quorum with 74.78% of votes represented, resulted in the election of two directors, the ratification of GBQ Partners LLC as the independent auditor, and the approval of the company’s reincorporation from Delaware to Nevada. Additionally, the 2025 Stock Incentive Plan was adopted, and executive compensation was approved to be reviewed every three years. These decisions are likely to impact the company’s governance and operational structure moving forward.
The most recent analyst rating on (CAPS) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
Capstone Holding Corp. reported record financial results for the third quarter of 2025, with a 19% year-over-year increase in pro forma revenue and a 46% rise in adjusted EBITDA. The company announced two acquisitions expected to contribute $26 million in annualized revenue, accelerating its path toward a $100 million run-rate by early 2026. The improved economic conditions and a favorable industry outlook, supported by interest rate cuts and a recovery in demand, provide strong long-term growth prospects for Capstone. The company has also achieved integration milestones with its recent acquisition, positioning itself for rapid post-close integration of future acquisitions.
The most recent analyst rating on (CAPS) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
On August 22, 2025, Capstone Holding Corp. completed its acquisition of Carolina Stone Holdings, LLC, and its subsidiary, Carolina Stone Distributors, LLC, from D22L, Inc. and other sellers. The transaction involved a cash payment of $2,625,000, subject to adjustments, and a seller note of $1,250,000. This acquisition is expected to enhance Capstone’s market presence in the stone products industry by expanding its operational capabilities and market reach.
The most recent analyst rating on (CAPS) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
Capstone Holding Corp. has entered into a securities purchase agreement with an institutional investor, authorizing the issuance of senior secured convertible notes. On October 22, 2025, Capstone issued a second convertible note worth $3,545,712.42, convertible into common stock at a price of $1.10 per share. The company received gross proceeds of $3,250,000 from this issuance and plans to file a registration statement with the SEC for the resale of the stock. Joseph Gunnar & Co., LLC acted as the sales agent for this financing.
The most recent analyst rating on (CAPS) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.